ADVIA Centaur PSA Immunoassay; Atellica IM Prostate-Specific Antigen (PSA)
Siemens Healthcare Diagnostics · Decision date Jul 16, 2025
What did the FDA decide?
FDA records P950021/S030 as a supplement to PMA P950021, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 16, 2025.
FDA approval order statement
Approval for the implementation of a particle size analyzer utilized for the in-process testing of paramagnetic particles.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Immunology
- Decision date
- Jul 16, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P950021/S030
- Regulatory pathway
- PMA supplement
- Applicant
- Siemens Healthcare Diagnostics
- Product code
- MTG
- Decision code
- OK30
- Decision date
- Jul 16, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions.
- Applicant
- Siemens Healthcare Diagnostics
- Product code
- MTG
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P950021/S030 received
Application receipt date recorded by FDA.
P950021/S030 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P950021. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MTG
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IMMULITE Systems Free PSAP060005/S027 | Siemens Medical Solutions Diagnostics Limited | PMA supplement | Sep 22, 2026 | FDA |
IMMULITE Systems Free PSAP060005/S026 | Siemens Medical Solutions Diagnostics Limited | PMA supplement | Aug 20, 2026 | FDA |
IMMULITE 2000 Free PSAP060005/S025 | Siemens Medical Solutions Diagnostics Limited | PMA supplement | Jul 27, 2026 | FDA |
| Siemens Healthcare Diagnostics, Inc. | PMA approval | May 11, 2026 | FDA | |
IMMULITE 2000 Free PSAP060005/S024 | Siemens Medical Solutions Diagnostics Limited | PMA supplement | Apr 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Siemens Healthcare Diagnostics
- Headquarters
- Not reported
- Brand website
- siemens-healthineers.com
- FDA applicant address
- 333 Coney St., East Walpole, MA, 02032
Sources and methodology
- Original FDA record: P950021/S030
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



